A form of gene therapy protects optic nerve cells and preserves vision in mouse models of glaucoma, according to research supported by NIH’s National Eye Institute. The findings suggest a way forward for developing neuroprotective therapies for glaucoma.

As regenerative therapies for blinding diseases move closer to clinical trials, the NEI's functional imaging consortium is pioneering noninvasive technologies to monitor the function of the retina’s neurons and their connections to the brain.

Researchers at the University of Wisconsin have developed a micro-molded scaffolding photoreceptor “patch” designed to be implanted under a damaged or diseased retina.

A team led by scientists at the National Eye Institute (NEI) has noninvasively visualized the light-sensing cells in the back of the eye, known as photoreceptors, in greater detail than ever before.

In a massive screen of 400 mouse genes, Yale School of Medicine researchers have identified 40 genes actively involved in suppression of axon regeneration in central nervous system cells.

A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy.

New generation CRISPR technology lays foundation for therapeutics to treat a wide range of inherited ocular diseases

The National Eye Institute (NEI) Audacious Goals Initiative (AGI) is exploring the possibility that the natural world holds the keys to restorative therapies that might unlock regenerative powers in humans.

A team of researchers has identified networks of genes that allow neurons to regenerate in animals like zebrafish.

NEI-funded scientists are hacking the zebrafish’s innate regenerative capacity to learn how to treat human disease.